Symbols / MCRB $8.80 -2.22% Seres Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
MCRB Chart
About

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 84.36M
Enterprise Value 123.48M Income 5.70M Sales 789.00K
Book/sh 4.63 Cash/sh 4.77 Dividend Yield —
Payout 0.00% Employees 66 IPO —
P/E 13.97 Forward P/E -0.96 PEG —
P/S 106.92 P/B 1.90 P/C —
EV/EBITDA -1.37 EV/Sales 156.50 Quick Ratio 2.40
Current Ratio 2.56 Debt/Eq 187.63 LT Debt/Eq —
EPS (ttm) 0.63 EPS next Y -9.17 EPS Growth —
Revenue Growth — Earnings 2026-05-06 ROA -42.25%
ROE 19.64% ROIC — Gross Margin 0.00%
Oper. Margin -44.24% Profit Margin 7.22% Shs Outstand 9.59M
Shs Float 7.28M Short Float 10.11% Short Ratio 9.26
Short Interest — 52W High 29.98 52W Low 6.53
Beta 0.29 Avg Volume 67.81K Volume 53.91K
Target Price $22.00 Recom Strong_buy Prev Close $9.00
Price $8.80 Change -2.22%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.00
Mean price target
2. Current target
$8.80
Latest analyst target
3. DCF / Fair value
$-103.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.80
Low
$22.00
High
$22.00
Mean
$22.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-13 main Canaccord Genuity Buy → Buy $22
2025-09-24 main Canaccord Genuity Buy → Buy $22
2025-05-08 down Chardan Capital Buy → Neutral $6
2025-03-20 main Chardan Capital Buy → Buy $1
2025-03-14 main Goldman Sachs Sell → Sell $1
2024-11-14 main Canaccord Genuity Buy → Buy $10
2024-11-13 main Chardan Capital Buy → Buy $1
2024-10-24 down JP Morgan Neutral → Underweight —
2024-09-13 main Canaccord Genuity Buy → Buy $10
2024-08-14 main Canaccord Genuity Buy → Buy $10
2024-08-14 main Chardan Capital Buy → Buy $1
2024-06-07 down Oppenheimer Outperform → Perform —
2024-06-07 main Canaccord Genuity Buy → Buy $10
2024-05-09 main Oppenheimer Outperform → Outperform $4
2024-05-08 main Chardan Capital Buy → Buy $6
2024-03-06 main Oppenheimer Outperform → Outperform $5
2024-03-06 main Chardan Capital Buy → Buy $8
2024-01-16 main Oppenheimer Outperform → Outperform $9
2023-11-03 main Goldman Sachs Sell → Sell $1
2023-04-28 main Chardan Capital — → Buy $10
News
RSS: Latest MCRB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-13 DESROSIER THOMAS J Chief Executive Officer — 244 — —
2026-02-13 SHAFF ERIC D Director — 723 — —
2026-02-13 HENN MATTHEW R Officer — 239 — —
2026-02-13 YOUNG TERESA L. Officer — 231 — —
2026-02-13 DESROSIER THOMAS J Chief Executive Officer — 78 $8.47 $661
2026-02-13 SHAFF ERIC D Director — 259 $8.47 $2,194
2026-02-13 HENN MATTHEW R Officer — 89 $8.47 $754
2026-02-13 YOUNG TERESA L. Officer — 75 $8.47 $635
2025-11-14 DESROSIER THOMAS J Chief Executive Officer — 244 — —
2025-11-14 SHAFF ERIC D Director — 721 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
144.93
Operating Revenue
0.00
0.00
0.00
-100.00%
144.93
Cost Of Revenue
3.53
0.00
0.00
—
Reconciled Cost Of Revenue
3.53
0.00
0.00
—
Gross Profit
-3.53
0.00
0.00
—
Operating Expense
117.78
-39.63%
195.10
+8.44%
179.91
-14.09%
209.42
Research And Development
64.60
-45.07%
117.60
+7.25%
109.65
-22.72%
141.89
Selling General And Administration
53.18
-31.38%
77.50
+10.30%
70.26
+1.45%
69.26
General And Administrative Expense
53.18
-31.38%
77.50
+10.30%
70.26
+1.45%
69.26
Salaries And Wages
22.68
-37.12%
36.07
+15.32%
31.28
+30.69%
23.93
Other Gand A
30.50
-26.37%
41.43
-41.03%
70.26
+1.45%
69.26
Other Operating Expenses
—
0.70
-29.88%
1.00
+157.97%
-1.73
Total Expenses
121.31
-37.82%
195.10
+8.44%
179.91
-14.09%
209.42
Operating Income
-121.31
+37.82%
-195.10
-8.44%
-179.91
-178.97%
-64.49
Total Operating Income As Reported
-121.31
+37.82%
-195.10
-8.44%
-179.91
-178.97%
-64.49
EBITDA
-120.30
+33.69%
-181.42
-6.14%
-170.93
-201.36%
-56.72
Normalized EBITDA
-125.99
+30.55%
-181.42
-6.14%
-170.93
-201.36%
-56.72
Reconciled Depreciation
5.47
-12.41%
6.24
-5.82%
6.63
+11.47%
5.95
EBIT
-125.77
+32.98%
-187.66
-5.69%
-177.56
-183.34%
-62.67
Total Unusual Items
5.68
0.00
0.00
0.00
Total Unusual Items Excluding Goodwill
5.68
0.00
0.00
0.00
Special Income Charges
5.68
0.00
0.00
0.00
Restructuring And Mergern Acquisition
—
—
—
0.00
Net Income
0.14
+100.12%
-113.72
+54.54%
-250.16
-281.46%
-65.58
Pretax Income
-125.77
+33.85%
-190.13
-3.57%
-183.58
-179.94%
-65.58
Net Non Operating Interest Income Expense
3.97
-17.92%
4.83
+263.17%
-2.96
-7305.00%
-0.04
Interest Expense Non Operating
0.00
-100.00%
2.47
-59.00%
6.02
+106.87%
2.91
Net Interest Income
3.97
-17.92%
4.83
+263.17%
-2.96
-7305.00%
-0.04
Interest Expense
0.00
-100.00%
2.47
-59.00%
6.02
+106.87%
2.91
Interest Income Non Operating
3.97
-45.66%
7.30
+138.75%
3.06
+6.55%
2.87
Interest Income
3.97
-45.66%
7.30
+138.75%
3.06
+6.55%
2.87
Other Income Expense
-8.42
-6385.82%
0.13
+119.01%
-0.70
+32.54%
-1.04
Other Non Operating Income Expenses
-14.11
-10627.61%
0.13
+119.01%
-0.70
+32.54%
-1.04
Gain On Sale Of Business
5.68
0.00
0.00
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
0.14
+100.12%
-113.72
+54.54%
-250.16
-281.46%
-65.58
Net Income From Continuing Operation Net Minority Interest
-125.77
+33.85%
-190.13
-3.57%
-183.58
-179.94%
-65.58
Net Income From Continuing And Discontinued Operation
0.14
+100.12%
-113.72
+54.54%
-250.16
-281.46%
-65.58
Net Income Continuous Operations
-125.77
+33.85%
-190.13
-3.57%
-183.58
-179.94%
-65.58
Net Income Discontinuous Operations
125.91
+64.79%
76.41
+214.77%
-66.58
—
Normalized Income
-131.46
+30.86%
-190.13
-3.57%
-183.58
-179.94%
-65.58
Net Income Common Stockholders
0.14
+100.12%
-113.72
+54.54%
-250.16
-281.46%
-65.58
Diluted EPS
0.00
+100.00%
-17.80
+61.47%
-46.20
-220.83%
-14.40
Basic EPS
0.00
+100.00%
-17.80
+61.47%
-46.20
-220.83%
-14.40
Basic Average Shares
7.77
+21.40%
6.40
+18.44%
5.40
+17.86%
4.59
Diluted Average Shares
7.77
+21.40%
6.40
+18.44%
5.40
+17.86%
4.59
Diluted NI Availto Com Stockholders
0.14
+100.12%
-113.72
+54.54%
-250.16
-281.46%
-65.58
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
139.81
-61.01%
358.60
+2.81%
348.78
-1.71%
354.86
Current Assets
38.67
-77.95%
175.41
-9.94%
194.76
-35.85%
303.63
Cash Cash Equivalents And Short Term Investments
30.79
-75.94%
127.97
-29.43%
181.34
-37.62%
290.71
Cash And Cash Equivalents
30.79
-75.94%
127.97
-21.51%
163.03
-9.43%
180.00
Other Short Term Investments
—
0.00
-100.00%
18.31
-83.46%
110.70
Receivables
4.75
0.00
0.00
0.00
Accounts Receivable
2.07
0.00
—
0.00
Other Receivables
2.68
—
—
—
Inventory
—
29.65
0.00
—
Raw Materials
—
4.43
0.00
—
Work In Process
—
25.22
0.00
—
Finished Goods
—
0.00
0.00
—
Prepaid Assets
—
—
—
12.92
Assets Held For Sale Current
0.00
-100.00%
39.40
—
—
Other Current Assets
3.13
-61.11%
8.05
-40.04%
13.42
+3.88%
12.92
Total Non Current Assets
101.14
-44.79%
183.19
+18.94%
154.02
+200.64%
51.23
Net PPE
92.44
-14.43%
108.03
-19.36%
133.97
+270.63%
36.15
Gross PPE
145.63
-7.30%
157.11
-12.23%
179.01
+134.26%
76.41
Accumulated Depreciation
-53.20
-8.39%
-49.08
-8.97%
-45.04
-11.85%
-40.27
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
8.45
+0.27%
8.42
+19.52%
7.05
+57.53%
4.47
Construction In Progress
0.86
-22.71%
1.11
-71.94%
3.97
+137.72%
1.67
Other Properties
105.37
-8.44%
115.08
-15.08%
135.52
+262.88%
37.34
Leases
30.95
-4.72%
32.49
+0.05%
32.47
-1.37%
32.92
Investments And Advances
—
—
0.00
-100.00%
0.49
Other Non Current Assets
8.70
-88.43%
75.16
+274.84%
20.05
+37.43%
14.59
Total Liabilities Net Minority Interest
126.03
-68.76%
403.46
+19.37%
338.00
+51.33%
223.35
Current Liabilities
41.22
-58.22%
98.66
+15.26%
85.60
+4.06%
82.26
Payables And Accrued Expenses
32.55
+24.47%
26.15
-66.16%
77.28
+104.82%
37.73
Payables
4.08
+12.03%
3.64
-93.03%
52.21
+280.12%
13.73
Accounts Payable
4.08
+12.03%
3.64
-79.12%
17.44
+26.97%
13.73
Current Accrued Expenses
28.47
+26.48%
22.51
-10.22%
25.07
+4.48%
24.00
Current Debt And Capital Lease Obligation
8.67
+55.25%
5.59
+37.71%
4.06
-38.62%
6.61
Current Debt
—
—
0.46
—
Other Current Borrowings
—
—
0.46
—
Current Capital Lease Obligation
8.67
+55.25%
5.59
+55.15%
3.60
-45.52%
6.61
Current Deferred Liabilities
—
7.73
+81.50%
4.26
-74.68%
16.82
Current Deferred Revenue
—
7.73
+81.50%
4.26
-74.68%
16.82
Other Current Liabilities
—
66.92
+92.47%
34.77
+64.80%
21.10
Total Non Current Liabilities Net Minority Interest
84.80
-72.18%
304.80
+20.76%
252.41
+78.89%
141.09
Liabilities Heldfor Sale Non Current
0.00
-100.00%
109.43
—
—
Long Term Debt And Capital Lease Obligation
82.97
-57.06%
193.20
+21.86%
158.53
+272.13%
42.60
Long Term Debt
—
101.54
+100.72%
50.59
+105.30%
24.64
Long Term Capital Lease Obligation
82.97
-9.48%
91.65
-15.09%
107.94
+501.08%
17.96
Non Current Deferred Liabilities
—
95.36
+3.17%
92.43
+6.24%
87.00
Non Current Deferred Revenue
—
95.36
+3.17%
92.43
+6.24%
87.00
Other Non Current Liabilities
1.84
+12.90%
1.63
+12.90%
1.44
-87.46%
11.49
Stockholders Equity
13.78
+130.73%
-44.86
-515.99%
10.78
-91.80%
131.51
Common Stock Equity
13.78
+130.73%
-44.86
-515.99%
10.78
-91.80%
131.51
Capital Stock
0.17
+28.15%
0.14
+8.00%
0.12
+35.87%
0.09
Common Stock
0.17
+28.15%
0.14
+8.00%
0.12
+35.87%
0.09
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
8.65
+28.11%
6.75
+7.84%
6.26
+36.27%
4.59
Ordinary Shares Number
8.65
+28.11%
6.75
+7.84%
6.26
+36.27%
4.59
Additional Paid In Capital
991.71
+6.26%
933.24
+6.63%
875.18
+17.34%
745.83
Retained Earnings
-978.10
+0.01%
-978.24
-13.15%
-864.51
-40.72%
-614.35
Gains Losses Not Affecting Retained Earnings
—
0.00
+100.00%
-0.01
+80.00%
-0.06
Other Equity Adjustments
—
—
-0.01
+80.00%
-0.06
Total Equity Gross Minority Interest
13.78
+130.73%
-44.86
-515.99%
10.78
-91.80%
131.51
Total Capitalization
13.78
-75.68%
56.69
-7.64%
61.37
-60.70%
156.15
Working Capital
-2.55
-103.32%
76.75
-29.69%
109.17
-50.69%
221.37
Invested Capital
13.78
-75.68%
56.69
-8.32%
61.83
-60.40%
156.15
Total Debt
91.64
-53.90%
198.78
+22.26%
162.59
+230.39%
49.21
Capital Lease Obligations
91.64
-5.76%
97.24
-12.82%
111.54
+354.02%
24.57
Net Tangible Assets
13.78
+130.73%
-44.86
-515.99%
10.78
-91.80%
131.51
Tangible Book Value
13.78
+130.73%
-44.86
-515.99%
10.78
-91.80%
131.51
Available For Sale Securities
—
—
—
0.49
Derivative Product Liabilities
0.00
-100.00%
0.55
0.00
—
Duefrom Related Parties Current
—
8.67
0.00
—
Dueto Related Parties Current
—
28.05
-19.32%
34.77
—
Investmentin Financial Assets
—
—
0.00
-100.00%
0.49
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-148.61
-26.63%
-117.35
+48.71%
-228.82
-3521.29%
6.69
Cash Flow From Continuing Operating Activities
-148.61
-26.63%
-117.35
+48.71%
-228.82
-3521.29%
6.69
Net Income From Continuing Operations
0.14
+100.12%
-113.72
+54.54%
-250.16
-281.46%
-65.58
Depreciation Amortization Depletion
5.47
-12.41%
6.24
-5.82%
6.63
+11.47%
5.95
Depreciation
5.47
-12.41%
6.24
-5.82%
6.63
—
Depreciation And Amortization
5.47
-12.41%
6.24
-5.82%
6.63
+11.47%
5.95
Other Non Cash Items
10.64
-29.83%
15.17
+118.78%
6.93
+70.39%
4.07
Stock Based Compensation
20.97
-38.50%
34.10
+33.82%
25.48
+26.01%
20.22
Asset Impairment Charge
3.27
0.00
0.00
—
Operating Gains Losses
-123.58
-174163.38%
0.07
—
—
Gain Loss On Investment Securities
-0.55
+64.86%
-1.55
—
—
Gain Loss On Sale Of PPE
0.32
0.00
0.00
0.00
Change In Working Capital
-65.51
-11.08%
-58.98
-220.68%
-18.39
-144.28%
41.53
Change In Receivables
6.61
+176.16%
-8.67
0.00
-100.00%
9.39
Changes In Account Receivables
-2.07
0.00
0.00
-100.00%
9.39
Change In Inventory
-33.80
-13.99%
-29.65
0.00
0.00
Change In Prepaid Assets
0.99
+103.39%
-29.12
-131.16%
-12.60
-2.12%
-12.34
Change In Payables And Accrued Expense
-28.84
-777.09%
4.26
-23.09%
5.54
-89.43%
52.39
Change In Accrued Expense
-25.90
-263.56%
15.84
+374.76%
3.34
-92.25%
43.02
Change In Payable
-2.94
+74.61%
-11.58
-625.56%
2.20
-76.47%
9.36
Change In Account Payable
-2.94
+74.61%
-11.58
-625.56%
2.20
-76.47%
9.36
Change In Other Working Capital
-4.12
-164.39%
6.41
+189.86%
-7.13
-63.60%
-4.36
Change In Other Current Liabilities
-6.34
-188.53%
-2.20
+47.73%
-4.20
-18.39%
-3.55
Investing Cash Flow
142.29
+1244.67%
10.58
-87.16%
82.43
+28.62%
64.09
Cash Flow From Continuing Investing Activities
142.29
+1244.67%
10.58
-87.16%
82.43
+28.62%
64.09
Net PPE Purchase And Sale
-0.38
+95.24%
-7.97
+18.80%
-9.82
-2.67%
-9.57
Purchase Of PPE
-0.38
+95.24%
-7.97
+18.80%
-9.82
-2.67%
-9.57
Capital Expenditure
-0.38
+95.24%
-7.97
+18.80%
-9.82
-2.67%
-9.57
Net Investment Purchase And Sale
0.00
-100.00%
18.56
-79.88%
92.25
+25.25%
73.65
Purchase Of Investment
0.00
+100.00%
-4.43
+90.82%
-48.22
+49.75%
-95.97
Sale Of Investment
0.00
-100.00%
22.98
-83.64%
140.47
-17.19%
169.62
Net Business Purchase And Sale
141.27
0.00
0.00
—
Gain Loss On Sale Of Business
-146.71
0.00
0.00
—
Net Other Investing Changes
1.40
—
—
—
Financing Cash Flow
-90.37
-226.03%
71.70
-44.67%
129.60
+10901.87%
1.18
Cash Flow From Continuing Financing Activities
-90.37
-226.03%
71.70
-44.67%
129.60
+10901.87%
1.18
Net Issuance Payments Of Debt
-127.91
-353.19%
50.52
+96.58%
25.70
+2810.86%
-0.95
Issuance Of Debt
0.00
-100.00%
103.38
+274.48%
27.61
0.00
Repayment Of Debt
-127.91
-141.97%
-52.86
-2671.89%
-1.91
-101.16%
-0.95
Long Term Debt Issuance
0.00
-100.00%
103.38
+274.48%
27.61
0.00
Long Term Debt Payments
-127.91
-141.97%
-52.86
-2671.89%
-1.91
-101.16%
-0.95
Net Long Term Debt Issuance
-127.91
-353.19%
50.52
+96.58%
25.70
+2810.86%
-0.95
Net Common Stock Issuance
23.53
+29.58%
18.16
-82.05%
101.17
0.00
Proceeds From Stock Option Exercised
0.49
-83.92%
3.03
+10.71%
2.73
+28.65%
2.13
Net Other Financing Charges
13.52
—
—
—
Changes In Cash
-96.69
-175.72%
-35.07
-108.91%
-16.79
-123.33%
71.95
Effect Of Exchange Rate Changes
-0.00
-150.00%
0.00
+300.00%
-0.00
+0.00%
-0.00
Beginning Cash Position
136.15
-20.48%
171.22
-8.93%
188.00
+62.00%
116.05
End Cash Position
39.46
-71.02%
136.15
-20.48%
171.22
-8.93%
188.00
Free Cash Flow
-148.99
-18.88%
-125.33
+47.48%
-238.64
-8191.77%
-2.88
Interest Paid Supplemental Data
10.86
-13.46%
12.55
+154.71%
4.93
+101.39%
2.45
Amortization Of Securities
0.00
+100.00%
-0.24
-134.30%
0.69
+38.15%
0.50
Common Stock Issuance
23.53
+29.58%
18.16
-82.05%
101.17
0.00
Issuance Of Capital Stock
23.53
+29.58%
18.16
-82.05%
101.17
0.00
Sale Of Business
141.27
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category